Trevi Therapeutics (TRVI) News Today $2.94 -0.12 (-3.92%) (As of 10/31/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 November 2021 Time Period Trevi Therapeutics (TRVI) Set to Announce Quarterly Earnings on WednesdayTrevi Therapeutics (NASDAQ:TRVI) will be releasing earnings after the market closes on Wednesday, November 6, Zacks reports.October 31 at 9:37 AM | marketbeat.comTrevi Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Corporate Update on November 6, 2024October 30 at 4:05 PM | prnewswire.comInside A Clothing Store In Rome Are The Best Hidden Views Of The Trevi FountainOctober 25, 2024 | msn.comTrevi Therapeutics (NASDAQ:TRVI) Given Buy Rating at HC WainwrightOctober 23, 2024 | americanbankingnews.comTrevi Therapeutics Positioned for Growth with Advancements in Chronic Cough Treatment and Undervalued Market PotentialOctober 22, 2024 | markets.businessinsider.comTrevi Therapeutics (NASDAQ:TRVI) Given "Buy" Rating at HC WainwrightHC Wainwright reiterated a "buy" rating and issued a $6.00 price target on shares of Trevi Therapeutics in a research note on Tuesday.October 22, 2024 | marketbeat.comStifel says Trevi’s RIVER enrollment completion puts data release in Q1 2025October 22, 2024 | markets.businessinsider.comTrevi Therapeutics completes enrollment for Phase 2a RIVER trialOctober 22, 2024 | markets.businessinsider.comBrokerages Set Trevi Therapeutics, Inc. (NASDAQ:TRVI) PT at $7.43October 22, 2024 | americanbankingnews.comTrevi Therapeutics Completes Enrollment for Phase 2a RIVER Trial in Refractory Chronic CoughOctober 21, 2024 | prnewswire.comGloria Trevi & Maria Becerra Dazzle With Daring ‘Borracha’ Performance at 2024 Latin Music AwardsOctober 21, 2024 | msn.comTrevi Therapeutics, Inc. (NASDAQ:TRVI) Receives Consensus Recommendation of "Buy" from AnalystsTrevi Therapeutics, Inc. (NASDAQ:TRVI - Get Free Report) has been assigned an average recommendation of "Buy" from the nine analysts that are presently covering the company, MarketBeat reports. Seven research analysts have rated the stock with a buy rating and two have given a strong buy rating toOctober 19, 2024 | marketbeat.comLeerink Partnrs Has Negative Outlook of TRVI FY2024 EarningsTrevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) - Stock analysts at Leerink Partnrs dropped their FY2024 earnings per share estimates for shares of Trevi Therapeutics in a research note issued on Tuesday, October 15th. Leerink Partnrs analyst F. Khurshid now forecasts that the company will eOctober 18, 2024 | marketbeat.comTrevi Therapeutics: Positive Outlook on Haduvio’s Potential Amid HAP Study InsightsOctober 17, 2024 | markets.businessinsider.comTrevi Therapeutics to Participate in Upcoming Commercial and Investor ConferencesOctober 15, 2024 | prnewswire.comRome Considers Entry Fee for Famed Trevi FountainOctober 12, 2024 | msn.comWhat happens to the millions of coins thrown into Rome’s Trevi Fountain?October 12, 2024 | apnews.comWhat happens to the millions of coins thrown into Rome's Trevi Fountain?October 11, 2024 | yahoo.comItaly: Changes for tourists in Rome: a walkway will be placed at the Trevi Fountain to regulate the number of visitorsOctober 11, 2024 | msn.comRome's Trevi Fountain Will Get a Much-Needed Cleaning—and a Controversial New Entry FeeOctober 11, 2024 | msn.comTrevi Therapeutics Inc (TRVI) Q2 2024 Earnings Call Highlights: Navigating Financial Challenges ...October 9, 2024 | finance.yahoo.comAccess to Rome’s Trevi fountain to be restricted in NovemberOctober 8, 2024 | msn.comVisitors To Get Rare View Of Rome's Trevi FountainOctober 8, 2024 | barrons.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Trevi Therapeutics (TRVI), Conmed (CNMD) and Revance Therapeutics (RVNC)October 4, 2024 | markets.businessinsider.comBuy Rating Affirmed on Trevi Therapeutics Amid Strong Clinical Trial Progress and Positive Upcoming MilestonesOctober 4, 2024 | markets.businessinsider.comTrevi Therapeutics (NASDAQ:TRVI) Given "Buy" Rating at Needham & Company LLCNeedham & Company LLC reiterated a "buy" rating and issued a $8.00 price objective on shares of Trevi Therapeutics in a report on Friday.October 4, 2024 | marketbeat.comTrevi Therapeutics, Inc.: Trevi Therapeutics Announces Appointment of James V. Cassella, Ph.D., as Chief Development OfficerOctober 4, 2024 | finanznachrichten.deMaintaining Buy Rating on Trevi Therapeutics Amid Anticipated Clinical Milestones for HaduvioOctober 4, 2024 | markets.businessinsider.comTrevi Therapeutics Provides Update on Haduvio's Clinical Development ProgramOctober 3, 2024 | prnewswire.comTrevi Therapeutics Announces Appointment of James V. Cassella, Ph.D., as Chief Development OfficerOctober 1, 2024 | stockhouse.comTrevi Therapeutics Announces Appointment of James V. Cassella, Ph.D.September 30, 2024 | prnewswire.comTrevi Warrior Women Walk taking place next weekendSeptember 28, 2024 | msn.comPromising Efficacy of Trevi’s Haduvio and Financial Stability Support Positive Outlook Despite Biotech RisksSeptember 27, 2024 | markets.businessinsider.comTrevi Therapeutics Announces Additional Analyses of Cough Relief Time from Ph2a CANAL Trial Accepted for Oral Presentation at CHEST 2024September 26, 2024 | prnewswire.comTrevi Therapeutics, Inc. (NASDAQ:TRVI) Stock Holdings Lifted by Logos Global Management LPLogos Global Management LP grew its position in shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) by 27.3% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 2,800,000 shares of the company's stock afSeptember 24, 2024 | marketbeat.comTrevi Therapeutics, Inc. (NASDAQ:TRVI) Given Average Recommendation of "Buy" by BrokeragesTrevi Therapeutics, Inc. (NASDAQ:TRVI - Get Free Report) has been assigned an average rating of "Buy" from the eight ratings firms that are presently covering the stock, MarketBeat.com reports. Six equities research analysts have rated the stock with a buy recommendation and two have assigned a stSeptember 24, 2024 | marketbeat.com1,474,926 Shares in Trevi Therapeutics, Inc. (NASDAQ:TRVI) Acquired by Ally Bridge Group NY LLCAlly Bridge Group NY LLC purchased a new stake in Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 1,474,926 shares of the company's stock, valued at apSeptember 23, 2024 | marketbeat.comRubric Capital Management LP Sells 537,192 Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI)Rubric Capital Management LP trimmed its position in Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) by 9.7% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,026,931 shares of the company's stock aSeptember 21, 2024 | marketbeat.comRome Tourism Chief Says There’s ‘Total Chaos’ at Trevi Fountain — Changes Are ComingSeptember 11, 2024 | skift.comAmid Crowding and Congestion, Rome’s Trevi Fountain Could Soon Limit AccessSeptember 11, 2024 | msn.comLeerink Partnrs Comments on Trevi Therapeutics, Inc.'s Q3 2024 Earnings (NASDAQ:TRVI)Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) - Equities research analysts at Leerink Partnrs issued their Q3 2024 earnings estimates for Trevi Therapeutics in a research report issued on Monday, September 9th. Leerink Partnrs analyst F. Khurshid forecasts that the company will post earninSeptember 11, 2024 | marketbeat.comQ1 2025 Earnings Estimate for Trevi Therapeutics, Inc. (NASDAQ:TRVI) Issued By Leerink PartnrsTrevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) - Equities research analysts at Leerink Partnrs issued their Q1 2025 earnings per share (EPS) estimates for Trevi Therapeutics in a research note issued to investors on Monday, September 9th. Leerink Partnrs analyst F. Khurshid anticipates thatSeptember 10, 2024 | marketbeat.comTrevi Therapeutics (NASDAQ:TRVI) Raised to "Strong-Buy" at Leerink PartnrsLeerink Partnrs upgraded shares of Trevi Therapeutics to a "strong-buy" rating in a research note on Monday.September 10, 2024 | marketbeat.comTrevi Therapeutics, Inc. (NASDAQ:TRVI) CEO Jennifer L. Good Sells 4,219 SharesSeptember 10, 2024 | insidertrades.comInsider Selling: Trevi Therapeutics, Inc. (NASDAQ:TRVI) CEO Sells 4,219 Shares of StockTrevi Therapeutics, Inc. (NASDAQ:TRVI - Get Free Report) CEO Jennifer L. Good sold 4,219 shares of the firm's stock in a transaction dated Friday, September 6th. The shares were sold at an average price of $3.03, for a total transaction of $12,783.57. Following the completion of the sale, the chief executive officer now owns 213,313 shares of the company's stock, valued at approximately $646,338.39. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.September 9, 2024 | marketbeat.comRome May Start Charging Tourists to See the Famous Trevi FountainSeptember 9, 2024 | yahoo.comYou may need tickets to visit Rome's Trevi FountainSeptember 9, 2024 | msn.comTrevi Therapeutics (NASDAQ:TRVI) Research Coverage Started at Leerink PartnersLeerink Partners initiated coverage on Trevi Therapeutics in a report on Monday. They issued an "outperform" rating and a $7.00 price objective on the stock.September 9, 2024 | marketbeat.comCity of Rome says it is planning to limit numbers of tourists at the Trevi Fountain as it struggles with overtourismSeptember 7, 2024 | yahoo.comRome could start charging tourists to visit the Trevi FountainSeptember 6, 2024 | apnews.com Get Trevi Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TRVI and its competitors with MarketBeat's FREE daily newsletter. Email Address $5k to $1.3m in just 3 trades (Ad)It doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade. Register for the imminent briefing here. TRVI Media Mentions By Week TRVI Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. TRVI News Sentiment▼0.630.68▲Average Medical News Sentiment TRVI News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. TRVI Articles This Week▼43▲TRVI Articles Average Week Get Trevi Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TRVI and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies VNDA News VYNE News CARA News PLRX News TYRA News ANAB News SANA News CRON News DNTH News ANNX News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:TRVI) was last updated on 10/31/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored“Buffett Indicator” Predicts 62% Stock Market CrashThe last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.Behind the Markets | SponsoredTrump or Kamala? It may come down to this strange twist…Could this be the key to America's second coming? A strange resurrection born in the hollers of Appalachia? ...Porter & Company | Sponsored625,000% GainThe recent pullback in the crypto markets has left many investors in full-on panic mode, convinced the bull ru...Crypto Swap Profits | SponsoredGold at $2,600... But This Stock Gives You More for Under $20Gold just soared over $2,600 an ounce. But what if I told you there's a way to get exposure to MORE than an...Monument Traders Alliance | SponsoredCNBC’s ‘Prophet’ issues urgent Fed warning"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Trevi Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Trevi Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.